Zoetis Liabilities 2024

Zoetis Aktienanalyse

What does Zoetis do?

Zoetis Inc. is a leading company in the development and marketing of animal health technology and solutions. The company specializes in innovative products for animals such as dairy cattle, pigs, poultry, dogs, cats, and horses. Zoetis was founded in 1952 as a subsidiary of Pfizer and operated as Pfizer Animal Health. In 2013, the company was finally spun off from Pfizer and became Zoetis Inc. Zoetis focuses on the development, manufacturing, and marketing of products for livestock and pets, including vaccines, pharmaceuticals, biological therapies, and diagnostics. The company operates globally and has its headquarters in Parsippany, New Jersey. Zoetis' business model consists of various business segments divided into animal categories: cattle, pigs, poultry, pets, and horses. Each of these business segments offers specialized solutions for animal owners and veterinarians. In the cattle products segment, Zoetis offers products for dairy cows, beef cattle, and calves. They also provide a variety of prevention and treatment solutions for major animal health issues such as mastitis, reproductive disorders, and respiratory problems. In the swine segment, Zoetis offers prevention and treatment solutions for infectious diseases and parasite control. They also provide products for promoting swine health and weight gain. In the poultry segment, Zoetis offers solutions for the prevention and treatment of infectious diseases. The company's products aim to improve animal health, productivity, and efficiency. Zoetis also offers products for the pet segment, including vaccines, pharmaceuticals, and therapies for dogs, cats, and other pets. Here, the company also provides solutions for major health issues such as heart diseases, pain management, and parasite control. In the horse segment, Zoetis offers solutions for the prevention and treatment of diseases such as equine rhinopneumonia, worm infestations, and arthritis. They also provide products for promoting horse health and performance. Zoetis is known for a variety of innovative products used by animal owners and veterinarians worldwide. One example is ScourGuard® 4KC, a vaccine that protects calves from diarrheal diseases caused by common bacteria. This vaccine has already proven to be highly effective in controlling bowel diseases in calves. Zoetis has also developed and marketed the first FDA-approved product for pain management in dogs (Rimadyl®), as well as the first licensed product for the treatment of giardia in dogs (Panacur®). In summary, Zoetis, as a global leader in the animal health industry, puts innovation and quality at the forefront. With a wide range of products and solutions in various animal categories, Zoetis is a key player in the animal health industry. Zoetis ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Zoetis's Liabilities

Zoetis's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Zoetis's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Zoetis's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Zoetis's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Zoetis’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Zoetis stock

What is the level of liabilities of Zoetis this year?

Zoetis has a debt balance of 9.29 B USD this year.

What were the liabilities of Zoetis compared to the previous year?

The liabilities of Zoetis have increased by -11.7% dropped compared to the previous year.

What are the consequences of high debt for investors of Zoetis?

High liabilities can pose a risk for investors of Zoetis, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Zoetis?

Low liabilities mean that Zoetis has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Zoetis affect the company?

An increase in liabilities of Zoetis can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Zoetis affect the company?

A decrease in the liabilities of Zoetis can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Zoetis?

Some factors that can influence the liabilities of Zoetis include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Zoetis so important for investors?

The liabilities of Zoetis are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Zoetis take to modify the liabilities?

To change its liabilities, Zoetis can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Zoetis pay?

Over the past 12 months, Zoetis paid a dividend of 1.5 USD . This corresponds to a dividend yield of about 0.86 %. For the coming 12 months, Zoetis is expected to pay a dividend of 2.03 USD.

What is the dividend yield of Zoetis?

The current dividend yield of Zoetis is 0.86 %.

When does Zoetis pay dividends?

Zoetis pays a quarterly dividend. This is distributed in the months of February, May, August, November.

How secure is the dividend of Zoetis?

Zoetis paid dividends every year for the past 18 years.

What is the dividend of Zoetis?

For the upcoming 12 months, dividends amounting to 2.03 USD are expected. This corresponds to a dividend yield of 1.16 %.

In which sector is Zoetis located?

Zoetis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zoetis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zoetis from 12/3/2024 amounting to 0.432 USD, you needed to have the stock in your portfolio before the ex-date on 10/31/2024.

When did Zoetis pay the last dividend?

The last dividend was paid out on 12/3/2024.

What was the dividend of Zoetis in the year 2023?

In the year 2023, Zoetis distributed 1.3 USD as dividends.

In which currency does Zoetis pay out the dividend?

The dividends of Zoetis are distributed in USD.